BTBD10

Across TCGA pan-cancer cohorts, BTBD10 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated BTBD10 data layer compared with 6 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher BTBD10 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated BTBD10 expression acts as an unfavorable survival marker, although some lineages such as KIRC and UCS show a favorable association.

MESO, LIHC, and KIRC are the cancer types where BTBD10 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.411	0.670	<.001	120	view →
LIHC	OS	Median	All	0.605	0.766	<.001	76	view →
KIRC	DFS	Median	All	0.878	0.716	<.001	59	view →
KICH	DFS	Tertile	II,III,IV	0.470	0.958	.002	59	view →
UVM	DFS	Tertile	All	0.305	0.726	.002	44	view →
PAAD	OS	Median	All	0.354	0.608	.006	33	view →
HNSC	OS	Tertile	IV	0.344	0.753	.001	28	view →
UCS	DFS	Tertile	IV	0.832	0.237	.024	24	view →
ACC	DFS	Tertile	II,III,IV	0.108	0.598	.005	21	view →
BRCA	DFS	Median	All	0.965	0.933	.002	20	view →
LGG	OS	Tertile	All	0.729	0.873	<.001	17	view →
LUSC	OS	Quartile	III,IV	0.208	0.529	.013	16	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

BTBD10–MESO (OS)

Open the MESO breakdown →